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Abstract
Summary We analysed data from elderly people registered
in the Swedish Prescribed Drug Register to investigate
whether age is associated with use of osteoporosis drugs in
a nationwide population. Our results indicate an undertreat-
ment of osteoporosis, particularly with bisphosphonates, in
the oldest old in Sweden.
Introduction The aim of this study was to investigate
whether age is associated with use of osteoporosis drugs
in a large population of older people.
Methods We analysed data on age, sex, type of residential
area (urban/rural) and dispensed drugs for people aged
≥75 years registered in the Swedish Prescribed Drug
Register from October to December 2005 (n=731,105).
Multivariate logistic regression was used to analyse
whether age was associated with use of osteoporosis drugs,
after adjustment for type of residential area and number of
other drugs (a proxy for comorbidity).
Results Osteoporosis drugs were used by 16.1% of the
women and 3.4% of the men. The probability of use of
bisphosphonates declined with increasing age [ORwomen=
0.36 (95% CI 0.34–0.38) and ORmen=0.46 (95% CI 0.37–
0.56) for age ≥90 years vs. 75–79 years]. Raloxifene was also
negatively associated with age. Calcium + vitamin D supple-
ments, however, showed a divergent pattern regarding age. In
women, the lowest likelihood of use of calcium + vitamin D
supplements occurred in the oldest old (≥90 years).
Conclusions Our results indicate an undertreatment of
osteoporosis, particularly with bisphosphonates, in the
oldest old in Sweden. Future research is needed for
understanding the mechanisms behind this age effect.
Keywords Bisphosphonates.Calcium+vitaminD
supplements.Drugregister.Elderly.Raloxifene.
Register-basedresearch
Introduction
Osteoporotic fractures are a fundamental cause of morbidity
and mortality [1, 2]. Hence, osteoporosis is a major public
health problem and imposes a substantial financial burden
to the society [1, 3–5]. The prevalence and costs associated
with osteoporosis is expected to increase even further due
to the ageing of the population [6, 7].
Advanced age is an important and independent risk
factor for osteoporosis and fractures [8]. Fracture risk is
much higher in the elderly than in the young, even given
the same bone mineral density (BMD) [8–11]. In Sweden,
regarded as a high-risk country for osteoporosis [8, 12],
about 47% of females and 17% of males aged 80–84 years
have osteoporosis [13], the mean age of hip fracture is
80 years for women and 76 years for men [14] and the
average 10-year probability of an osteoporotic fracture is
about 27% for women and 13% for men aged 85 years [11].
Therefore, one would expect that use of osteoporosis
drugs increases with increasing age. However, there are
indications that the oldest old may be undertreated for
osteoporosis [15–18]. Studies have shown that it is
particularly cost-effective to treat osteoporosis at higher
ages [19], and people with advanced ages are well-
represented in randomised clinical trials (RCTs) of phar-
macological treatment of osteoporosis compared to other
geriatric disorders. Thus, there is sufficient documentation
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as concluded by The Swedish Council on Technology
Assessment in Health Care [20, 21].
The aim of this study was to investigate whether age is
associated with use of osteoporosis drugs (i.e., bisphosph-
onates, calcium + vitamin D supplements and raloxifene) in
a large population of older people.
Materials and methods
Study population
The individual-based Swedish Prescribed Drug Register
(SPDR) was introduced in July 2005 and contains data with
unique personal identification numbers for all dispensed
prescriptions to the whole population of Sweden (about
nine million inhabitants). The data collection is adminis-
tered by the state-owned National Corporation of Swedish
Pharmacies and then transferred to the Centre for Epidemi-
ology at the National Board of Health and Welfare, which is
responsible for keeping the register [22]. The SPDR is
intended for epidemiological studies, research and statistics
within the health care area. Missing data due to personal
identification number is about 0.3% [23].
We analysed non-identifiable data from individuals aged
≥75 years who were registered in the SPDR from October
to December 2005, with information about every individ-
ual’s age, sex, type of residential area (urban/rural) and
dispensed drugs (amount of prescribed drug, when the
prescription was filled, and prescribed dosage (i.e., from the
prescriptions written by the prescribers)). After exclusion of
the 0.2% (1,125/732,230) individuals with missing data on
place of residence, the study population consisted of
731,105 older people (450,482 women and 280,623 men).
Information from the 3-month period about when the
prescription was filled, the amount of drug and the
prescribed dosage was processed to calculate the duration
of drug exposure [24, 25]. When the prescribed dosage was
incomplete or missing, we used defined daily doses
(DDDs) [26] to calculate the duration of drug exposure.
The DDD is the assumed average dose per day for a drug
used for its main indication in adults [26]. We assumed 0.9
DDDs for regularly used drugs (based on calculations for
regularly used drugs among the elderly in the study
population) and 0.45 DDDs (50% of 0.9) for drugs
prescribed as needed, as indicated on the prescription. In
addition, we assumed one DDD for dermatological and eye
preparations.
A list of current prescriptions was constructed based on
the calculations of the duration of drug exposures for every
individual on the arbitrarily chosen date of 31 December
2005. If a patient was dispensed the same drug in different
doses during the study period, this was counted as one
dispensed drug.
This study was approved by the ethical board in
Stockholm (Dnr 2006/948-31).
Definitions
Osteoporosis drugs were classified according to their
Anatomical Therapeutic Chemical code [26] (M05BA and
M05BB for bisphosphonates (etidronic acid, clodronic acid,
pamidronic acid, alendronic acid, ibandronic acid, rise-
dronic acid and zoledronic acid), A12AX for the combina-
tion of calcium + vitamin D and G03XC01 for raloxifene).
Patients on several osteoporosis drugs were categorised as
users of all separate drugs. Calcitonin was used by only 20
people, and, therefore, excluded from this study. We also
excluded hormone replacement therapy (HRT) because
these drugs were in 2005 mainly used for treatment of
climacteric symptoms.
Age was categorised into four groups: 75–79 (reference),
80–84, 85–89 and ≥90 years. Number of other drugs, used
as a proxy for comorbidity [27, 28], consisted of the
number of prescriptions filled by the person other than the
osteoporosis drugs under study (i.e., bisphosphonates,
calcium + vitamin D supplements and raloxifene). This
variable was divided into four categories: 0–4 (reference),
5–9, 10–14 and ≥ 15 drugs.
Type of residential area was classified according to a
Statistics Sweden scale into six categories of so called
homogeneity regions (H1–H6) depending on the population
density and the number of inhabitants in the nearest vicinity
of the main city in that municipality [29].
According to this official homogeneity region classifi-
cation, the two highest density categories (H1, H2) include
only the largest cities in Sweden: Stockholm, Göteborg and
Malmö/Lund. H3 consists of municipalities with more than
90,000 inhabitants within a 30 km radius from the centre of
that municipality. H4 includes municipalities with more
than 27,000 but less than 90,000 inhabitants from the centre
of that municipality and also more than 300,000 inhabitants
within a 100 km radius from the same centre. H5 is
identical to H4 except that there are less than 300,000
inhabitants from the centre of the municipality. Finally, H6
consists of municipalities with less than 27,000 inhabitants
within a radius of 30 km from the municipality centre. H4–
H6 were classified as rural (reference) and H1–H3 as urban
areas [30].
Statistical analysis
Men and women were analysed separately. Multivariate
logistic regression was used to analyse whether age was
18 Arch Osteoporos (2009) 4:17–23associated with filled prescription of osteoporosis drugs,
after adjustment for type of residential area and number of
other drugs. The results are shown as odds ratios (ORs)
with 95% confidence intervals (CIs). SPSS 14.0 for
Windows (SPSS, 1989–2005) was used for the analyses.
Results
Mean age among the 731,105 elderly was 82.5 years in
women and 81.4 years in men (Table 1). Osteoporosis
drugs were used by 16.1% of the women (bisphosphonates,
5.4%; calcium + vitamin D supplements, 14.2% and
raloxifene, 0.3%) and 3.4% of the men (bisphosphonates,
0.9% and calcium + vitamin D supplements, 3.1%). The
users of bisphosphonates and raloxifene were younger than
the non-users of osteoporosis drugs, whereas the male users
of calcium + vitamin D supplements were older (Table 1).
Figures 1, 2 and 3 show that the prevalence of the three
types of osteoporosis drugs was lowest in the oldest old
(≥90 years), except for calcium + vitamin D supplements
among men. The prevalence of bisphosphonates decreased
after 80–84 years, particularly in women (Fig. 1). The use
of calcium + vitamin D supplements was most common in
the age group 85–89 years (Fig. 2), whereas the prevalence
of raloxifene decreased with increasing age throughout the
age span (Fig. 3).
Furthermore, users of osteoporosis drugs had on average
more non-osteoporosis drugs than the non-users (Table 1).
Also, users of osteoporosis drugs lived in urban areas to a
greater extent than the non-users.
The multivariate logistic regression analyses (Table 2)
showed that the probability of use of bisphosphonates
declined with increasing age [ORwomen=0.36 (95% CI
0.34–0.38) and ORmen=0.46 (95% CI 0.37–0.56) for age
≥90 years compared with 75–79 years], after adjustment for
type of residential area and number of other drugs.
Raloxifene was also negatively associated with age
[ORwomen=0.24 (95% CI 0.18–0.32) for age ≥90 years
compared with 75–79 years]. Calcium + vitamin D supple-
ments, however, showed a divergent pattern. In men, these
drugs showed an increased probability of use with age,
although there was a slight decrease in those aged ≥90 years
compared with 85–89 years. In women, the lowest
likelihood of use of calcium + vitamin D supplements
occurred in the oldest old [ORwomen=0.81 (95% CI 0.78–
0.83) for age ≥90 years compared with 75–79 years]. Use
of osteoporosis drugs, particularly raloxifene, was associat-
ed with living in an urban area (Table 2). Moreover, use of
other drugs was strongly associated with osteoporosis drug
use, particularly in men.
Discussion
Main findings
In our nationwide population of older people, about 16% of
the women and 3% of the men used any osteoporosis drug,
which is low compared with the estimated osteoporosis oc-
currence in Sweden [13]. Thus, it seems like osteoporosis is
undertreated in elderly Swedes and particularly in the oldest
old (≥90 years). These findings are in concordance with
results from previous studies regarding age and treatment
with osteoporosis drugs [15, 28, 31, 32]. One reason for this
finding may include physicians’ wish to minimise polyphar-
Table 1 Characteristics of the study population according to use of osteoporosis drugs, 2005
Study
population
Non-users of
osteoporosis drugs
Users of
bisphosphonates
Users of calcium +
vitamin D
Users of
raloxifene
Women
n 450,482 377,748 24,439 63,831 1,255
Mean age (years±SD) 82.5±5.4 82.6±5.5 81.5±4.6 82.6±5.2 80.7±4.4
Type of residential area (n (%))
Urban 299,171 (66.4) 247,293 (65.5) 17,307 (70.8) 45,713 (71.6) 1,003 (79.9)
Rural 151,311 (33.6) 130,455 (34.5) 7,132 (29.2) 18,118 (28.4) 252 (20.1)
Mean number of other drugs (no. ± SD) 5.4±3.9 5.2±3.8 6.3±4.4 6.5±4.3 5.8±4.2
Men
n (%) 280,623 270,965 2,478 8,799 –
Mean age (years ± SD) 81.4±4.9 81.4±4.9 80.9±4.3 82.0±4.8
Type of residential area (n (%))
Urban 180,921 (64.5) 174,197 (64.3) 1,685 (68.0) 6,177 (70.2)
Rural 99,702 (35.5) 96,768 (35.7) 793 (32.0) 2,622 (29.8)
Mean number of other drugs (no. ± SD) 5.1±3.7 5.0±3.7 7.1±4.4 7.1±4.3
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was strongly associated with use of osteoporosis drugs [28,
32], so this explanation seems less probable. Other explan-
ations might be physicians’ and elderly patients’ attitudes and
knowledge of osteoporosis and osteoporosis drugs, older
patient’s lack of communication skills (maybe due to cog-
nitive impairment) and non-adherence in the oldest old [33].
The prevalence of bisphosphonates was generally low
(5% for women and 1% for men) and higher age,
particularly in women, was associated with decreased use
of bisphosphonates. Treatment with bisphosphonates is
well-documented in the elderly and these drugs have an
overall favourable safety profile [6, 8, 34]. The cost-
effectiveness of bisphosphonates in the elderly has also
been established [8, 35–37]. Thus, there seem to be
opportunities for improvement in treatment with bisphosph-
onates in older Swedes. Nevertheless, the Hip Intervention
Program Study Group concludes that the bisphosphonate
risedronate reduces the risk of hip fracture in elderly
women with confirmed osteoporosis but not in elderly
women selected primarily on the basis of risk factors other
than low BMD [38]. The selective oestrogen receptor
modulator raloxifene is a newer type of osteoporosis drug,
and, hence, not as well-studied as the bisphosphonates.
Raloxifene is mainly regarded as suitable for postmeno-
pausal women, who would previously been prescribed HRT
[15, 34], which would explain the decreased use in the
older participants in our study.
The most common type of osteoporosis drug was
calcium + vitamin D supplements, which is in concordance
with previous research [31]. Calcium + vitamin D supple-
ments are regarded as less potent than bisphosphonates and
raloxifene, and are most likely only effective in deficient
patients [8, 34]. In women, the prevalence and likelihood of
use of calcium + vitamin D supplements were lowest in the
oldest old, even though frail older women confined to
institutions sustain fewer fractures if given calcium +
vitamin D supplements [39]. To our knowledge, there are
no evidence-based guidelines supporting a reduced use in
the oldest old women.
In concordance with previous studies [17, 31, 32, 40,
41], it seems as if men are particularly undertreated for
osteoporosis, although mortality for most osteoporotic
fractures has been reported to be higher in men than in
women [42]. Nevertheless, osteoporosis in men has only
recently been broadly recognised [43] and the treatment
rates may be expected to increase as the awareness of male
osteoporosis improves. Moreover, the stronger association
observed in our study between use of other drugs and use of
osteoporosis drugs in men, indicates that males treated for
osteoporosis may have more comorbid conditions than their
female counterparts. Thus, men seem to be in a worse
condition than women when treated for osteoporosis.
Furthermore, living in an urban area was associated with
a higher probability of osteoporosis treatment. Explanations
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Fig. 1 Prevalence of bisphosphonates according to age (450,482
women and 280,623 men)
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Fig. 2 Prevalence of calcium + vitamin D supplements according to
age (450,482 women and 280,623 men)
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Fig. 3 Prevalence of raloxifene according to age (450,482 women)
20 Arch Osteoporos (2009) 4:17–23for this finding may be a higher rate of osteoporosis and
fractures in urban areas [44–47] longer distance to BMD
testing in rural areas [28] and availability of specialist care.
Limitations
The cross-sectional design of our study does not allow us to
draw conclusions regarding causality. The SPDR does not
include information about the underlying indications and
diagnoses for prescription of drugs. We also lacked
information about comorbidity. However, we did control
for a proxy for overall comorbidity (i.e., number of other
drugs) [27, 28].
We analysed data on elderly patients registered in the
SPDR from October to December 2005, which corre-
sponded to 91% of the population aged 75 years and older
in Sweden (according to Statistics Sweden’s census data
from 31 December 2005). The SPDR does not include data
on over-the-counter drugs, which only concerns calcium +
vitamin D supplements in this study. Calcium + vitamin D
supplements can be purchased both with and without a
prescription in Sweden. However, we were specifically
interested in prescribing practise regarding osteoporosis
drugs. Therefore, the lack of information about use of non-
prescription drugs was not a substantial problem in this
particular study. Also, the register does not include drugs
used in hospitals or from drug storerooms sometimes used
in nursing homes, which may lead to an underestimation of
older people’s drug use. Moreover, our method is built on
an assumption that all current drugs were dispensed during
the observed 3-month period, which is based on the fact
that drugs are prescribed for use during at most 90 days in
Sweden. Therefore, we might have missed drugs that were
dispensed before the 3-month period and used at a slower
rate than intended. At the same time, we might have
included drugs that were dispensed during the 3-month
Table 2 Adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) for dispensed osteoporosis drugs in 450,482 women and 280,623
men in Sweden, 2005
Bisphosphonates OR (95% CI) Calcium + vitamin D supplements OR
(95% CI)
Raloxifene OR
(95% CI)
Women
Age (years)
75–79 Ref Ref Ref
80–84 0.95 (0.93, 0.98) 1.06 (1.04, 1.08) 0.76 (0.67, 0.86)
85–89 0.75 (0.72, 0.77) 1.02 (1.00, 1.05) 0.48 (0.40, 0.56)
≥90 0.36 (0.34, 0.38) 0.81 (0.78, 0.83) 0.24 (0.18, 0.32)
Type of residential area
Rural Ref Ref Ref
Urban 1.25 (1.21, 1.29) 1.34 (1.31, 1.36) 2.03 (1.76, 2.33)
Number of other drugs
0–4 Ref Ref Ref
5–9 1.40 (1.36, 1.44) 1.60 (1.57, 1.63) 1.12 (0.99, 1.27)
10–14 1.94 (1.86, 2.01) 2.19 (2.13, 2.25) 1.56 (1.32, 1.85)
≥15 2.63 (2.47, 2.80) 2.77 (2.66, 2.89) 1.70 (1.26, 2.28)
Men
Age (years)
75–79 Ref Ref –
80–84 1.00 (0.92, 1.10) 1.19 (1.13, 1.25)
85–89 0.79 (0.71, 0.89) 1.25 (1.18, 1.33)
≥90 0.46 (0.37, 0.56) 1.10 (1.01, 1.20)
Type of residential area
Rural Ref Ref
Urban 1.16 (1.07, 1.26) 1.30 (1.24, 1.36)
Number of other drugs
0–4 Ref Ref
5–9 2.05 (1.86, 2.25) 2.15 (2.04, 2.26)
10–14 3.36 (2.99, 3.78) 3.40 (3.19, 3.62)
≥15 5.61 (4.74, 6.64) 5.07 (4.61, 5.58)
Arch Osteoporos (2009) 4:17–23 21period but discontinued prematurely. In addition, our
method is based on interpretations of the dispensed drugs’
dosages written by the prescribers, as well as assumptions
about DDDs when information about dosage was incom-
plete or missing (about 15% of the regularly used drugs)
[24, 25].
Finally, a general limitation of studies on drug registers
is that data on dispensed drugs are not synonymous with
neither prescribed nor used drugs. Some prescriptions may
never be filled at pharmacies and adherence to treatment
can be low [33].
Conclusions
Our results indicate an undertreatment of osteoporosis, par-
ticularly with bisphosphonates, in the oldest old in Sweden.
Future research in other large study populations is needed for
understanding the mechanisms behind this age effect.
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